2-DG: Dr. Reddy’s announces the launch of an anti-Covid-19 drug; MRP set at Rs 990/envelope
2-deoxy-D-glucose (2DG) is an oral antiviral drug for Covid-19 patients. The drug sparked a lot of interest after it was presented on May 17 through the Ministry of Defense. It evolved through the Institute of Nuclear Medicine and Allied Sciences (INMAS), one of the main laboratories of the DRDO, in collaboration with Dr. Reddy Laboratories (DRL) in Hyderabad.
2-DG has a purity of 99. 5% and will be sold commercially under the logo called 2DG.
Dr. Reddy’s will source from state governments and private hospitals across the country. In the first few weeks, the company will manufacture the drug to be available in hospitals in metropolises and tier 1 cities, and then expand its policy to the rest of India. .
The pharmaceutical company said it began mass production of the drug in the first week of June. The drug will be delivered to the government at a reduced price.
India’s Comptroller General of Medicines (DGCI) had the oral drug for emergency use as an adjunct treatment to treat severe Covid patients.
According to the Ministry of Defence, the drug, in clinical trials, has been shown to facilitate faster recovery for hospitalised Covid patients and reduce reliance on supplemental oxygen. A higher proportion of patients treated with 2-DG showed negative RT-PCR conversion to COVID. patients.
In April 2020, the first wave of the pandemic, INMAS-DRDO scientists conducted laboratory experiments with the help of the Centre for Cellular and Molecular Biology (CCMB) in Hyderabad and found that this molecule worked well against SARS-CoV-2. virus and inhibited viral growth.
READ MORE: DRDO’s 2-DG drug launched to treat Covid-19 patients; oxygen dependency
READ MORE: DRDO EoI to move 2-DG drug generation to bulk production
© 2009-2024 Independent Press Service. All rights reserved.